Alopectyl

Quick links to important sections

Alopectyl

Method of action: Endocrine Therapy

Treatment option: Anorexia, Cachexia, Cancer, Breast Cancer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alopectyl

Alopectyl is the commercial name for a prescription medication whose active component is Megestrol acetate (INN). It is a highly specialized pharmaceutical product categorized by its actions as a synthetic progestogen and a hormonal antineoplastic agent.

Property Description
Active ingredient Megestrol acetate
Form Tablet (Oral), Oral suspension (Liquid)
Pharmacological class Progestin, Antineoplastic Agent
General purpose Hormonal modulation and Appetite stimulation
Origin Synthetic derivative of Progesterone

What Type of Medicine is Alopectyl, and How is it Classified?

Alopectyl is classified as a Progestin, an agent specifically designed to interact with the body's progesterone receptors. The compound, Megestrol acetate, is a chemically modified, steroidal derivative of the natural hormone progesterone. The structural modification of this molecule enhances its activity and allows it to function as a strong agonist of the progesterone receptor. This defining characteristic is medically recognized for its ability to influence hormone-sensitive biological processes.

Megestrol acetate is classified as an Antineoplastic Agent, Hormonal, and an Appetite Stimulant. This combined classification is essential for understanding the drug's intended application profile.


Composition and General Purpose

Alopectyl is a single-active-ingredient product available as a solid tablet or a liquid oral suspension for oral administration. The suspension relies on micronized Megestrol acetate in an aqueous vehicle to achieve reliable absorption. A unique aspect of the suspension is its formulation for optimal oral bioavailability, which is particularly relevant for the patient group often experiencing nutritional challenges.

The general utility of Alopectyl is characterized by its dual physiological actions: providing necessary hormonal modulation and functioning as a highly effective appetite stimulant or orexigenic agent. This capacity for hormonal influence and the ability to influence metabolic signals allow the medication to generally address serious conditions involving systemic wasting, profound loss of body mass, or severe, involuntary weight loss, scientifically termed cachexia.

Regulatory References

  1. Megestrol Acetate MeSH Entry (NLM)
  2. StatPearls - Megestrol Acetate

What side effects are possible with Alopectyl?

Possible Side Effects and Safety Information

Alopectyl (Megestrol acetate) is classified as a progestogen and hormonal antineoplastic agent, and its safety profile is defined by officially documented adverse reactions and strict regulatory constraints based on government labeling.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency observed in clinical studies. Reactions classified as Most Common (occurring in more than 5% of patients) include Diarrhea, Impotence (erectile dysfunction), Rash, Flatulence, Hypertension (high blood pressure), Asthenia (unusual weakness), and Nausea. Other reactions affect the Gastrointestinal, Metabolic, Nervous, and Reproductive Systems.


Serious Adverse Reactions and Safety Constraints

Regulatory warnings highlight potential serious risks associated with treatment:

  • Thromboembolic Events: There is an increased risk of serious blood clots, such as Deep Venous Thrombosis (DVT) and Pulmonary Embolism.
  • Adrenal Dysfunction: Chronic use can lead to Adrenal Suppression, potentially resulting in Cushing's Syndrome or Adrenal Insufficiency upon treatment withdrawal.
  • Metabolic Risks: The medication carries a risk of New Onset Diabetes Mellitus or the exacerbation of pre-existing diabetes.

Population-Specific Restrictions

Government labeling defines specific usage limitations for certain patient groups:

  • Pregnancy: Alopectyl is strictly Contraindicated in known or suspected pregnancy due to the risk of fetal harm.
  • Breastfeeding: Treatment requires discontinuation of breastfeeding due to potential adverse effects on the newborn.
  • Older Adults: Caution is advised due to the greater risk of age-related organ dysfunction and increased risk of thromboembolic events.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Alopectyl (Megestrol acetate) details specific manifestations reported in post-marketing experience following an overdose. The documented clinical signs and symptoms have included gastrointestinal issues such as diarrhea, nausea, and abdominal pain. Other effects reported include cough, shortness of breath, chest pain, unsteady gait, and listlessness. Regulatory studies involving administration in doses as high as 1600 mg/day have not resulted in any serious unexpected side effects.

Emergency Action and Supportive Management

In the event of an overdose, the mandatory regulatory instruction is to take appropriate supportive measures. Official labeling confirms that no specific antidote is known for megestrol acetate, and due to the drug’s low solubility, dialysis is postulated to be ineffective as a treatment method.

Immediate medical assistance is required when severe manifestations are present. Emergency services must be called immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened. This guidance establishes the specific, potentially life-threatening outcomes that necessitate urgent medical intervention as outlined in the government-published information.

Therapeutic Uses of Alopectyl

What Alopectyl Treats: Main Uses and Benefits

Counteracting Severe Wasting Syndrome (Cachexia) and Anorexia

Alopectyl (Megestrol acetate) is relevant across two critical, specialized therapeutic domains: providing supportive care against profound wasting and managing specific hormone-dependent cancers. The focus is on symptomatic relief and support in advanced disease contexts, and the medication is commonly used for both distinct purposes.

This medication is applied in addressing the severe, involuntary loss of body weight and lean body mass, known as cachexia, along with the associated symptom of profound appetite suppression (anorexia). It is relevant for managing symptoms that interfere with daily comfort. The medication is used for specific chronic wasting illnesses as well as advanced or recurrent malignancies, including breast carcinoma and endometrial carcinoma. This application is commonly used when supportive symptom management is appropriate to help maintain functional stability.

Palliative Hormonal Treatment for Certain Cancers

Alopectyl is used as a systemic hormonal palliative agent for patients with specific advanced or recurrent malignancies in conditions where additional supportive symptom management is appropriate. This application is relevant in areas where additional symptomatic support is needed. It may assist with managing symptoms related to the advancement of these conditions, supporting the patient during difficult episodes by easing distress.


Quick Fact: Supportive Management for Profound Anorexia Alopectyl is commonly used to help with severe appetite loss and involuntary weight decline, supporting patients by contributing to increased caloric intake and supporting the maintenance of functional stability during chronic wasting phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Alopectyl (Megestrol Acetate)

Regulatory documents strictly define the population eligible to use Alopectyl, focusing on specific exclusions, age limitations, and conditional use requirements. The medicine is primarily approved for use in adults for its indicated purposes.


Absolute Contraindications

Contraindicated Group Regulatory Status
Pregnancy Contraindicated (Potential for fetal harm). Women of childbearing potential must use effective contraception.
Hypersensitivity Contraindicated in patients with a known allergy to Megestrol acetate or formulation components.

Age and Condition-Based Restrictions

Population or Condition Regulatory Status
Pediatric Patients Not recommended; safety and effectiveness have not been established by regulators.
Older Adults Use requires caution, often starting at lower doses, due to increased frequency of reduced organ function.
Thromboembolic Disease Use requires caution and close surveillance in patients with a history of blood clots.
Renal/Hepatic Impairment Use requires caution due to known renal excretion and the need for close monitoring.
Lactation Not recommended; breastfeeding should be discontinued if treatment is necessary.

Eligibility is limited to these defined populations, strictly excluding use in populations where safety is unestablished or where formal contraindications exist according to official prescribing information.

What should I know about interactions with other medicines?

Alopectyl (a combination product containing butalbital, acetaminophen, caffeine, and codeine) interacts with various medicines, primarily due to the central nervous system (CNS) effects of butalbital and codeine, and the metabolic pathway of codeine and acetaminophen.

High-Risk Interactions and Restrictions

Category Interaction Risk & Regulatory Status
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated. Do not use concurrently due to risk of serious adverse reactions.
Benzodiazepines & CNS Depressants High risk. Concomitant use with benzodiazepines, other CNS depressants, or alcohol may result in profound sedation, respiratory depression, coma, and death. Prescribing is reserved for when alternatives are inadequate, and dosage/duration must be limited.
Serotonergic Drugs Concomitant use may lead to the development of serotonin syndrome, which is a potentially life-threatening condition. Discontinue this product if serotonin syndrome is suspected.

Other Significant Interactions

  • Mixed Agonist/Antagonist or Partial Agonist Opioid Analgesics should be avoided, as they may reduce the analgesic effect of Alopectyl or precipitate withdrawal symptoms.
  • Cytochrome P450 (CYP) Enzyme Inhibitors and Inducers may alter how codeine is metabolized into its active form, morphine. Inhibitors of CYP3A4 and CYP2D6 can impact the drug's effects and should be carefully considered, requiring close monitoring. The acetaminophen component also carries a risk of liver damage (hepatotoxicity), which is heightened by chronic alcohol consumption.

Mechanism of Action

How Alopectyl Works: Mechanism of Action

Primary Targeting of Receptor-Mediated Signaling

Alopectyl's mechanism begins with its specific action as a selective modulator on the [Insert Specific Receptor/Enzyme Name] site. This primary interaction allows the drug to focus its activity precisely on processes governed by this key biological target, aiming to influence signaling patterns associated with specific physiological signaling patterns.

Interference with Signal Transduction Cascades

Following target engagement, Alopectyl actively modifies the downstream molecular cascade (e.g., the [Insert Relevant Pathway Name, e.g., cAMP/ PKA pathway]), effectively modulating the amplification of the cellular signal. This targeted interference is relevant to the modulation of activity within the affected neural or humoral pathways.

Influencing Physiological Regulation and Systems

The overall mechanism modulates overactive or dysregulated physiological processes by influencing activity levels within central and peripheral systems. By influencing the core mechanisms underlying these responses, Alopectyl influences the activity level within the targeted pathways, which determines the downstream physiological consequence.

Dosage and Administration Information

How to Use Alopectyl: Official Administration Guidelines

Alopectyl (Megestrol acetate) is administered exclusively by the oral route, available in both tablet and liquid oral suspension forms. Official usage protocols define specific dosing schedules and administration requirements for each labeled use.

Administration Scope and Dosing

Feature Official Instruction
Dosing Schedule (Tablets) Breast Carcinoma: 160 mg per day, typically as 40 mg four times daily (q.i.d.). Endometrial Carcinoma: 40 mg to 320 mg per day in divided doses.
Dosing Schedule (Suspension) Anorexia/Cachexia: The dose is administered once daily. The dose is 800 mg/day for the 40 mg/mL strength or 625 mg/day for the concentrated 125 mg/mL strength.
Preparation & Timing The oral suspension container must be shaken well before each use. The concentrated 125 mg/mL strength may be taken without regard to meals.

Procedural and Course Constraints

For certain uses, at least two months of continuous administration is considered an adequate period for determining the intended effect. A critical administration rule mandates that the concentrated 125 mg/mL oral suspension is not substitutable with the 40 mg/mL strength on a milligram-for-milligram basis due to differences in absorption profiles. For older adults, dose selection should be cautious, typically starting at the low end of the official dosing range.

This official protocol defines how the medicine must be prepared and delivered, ensuring the correct strength is used at the specified frequency, whether administered once daily or in divided doses.

Recent Clinical Evidence

Alopectyl: Recent Clinical Evidence

This section provides a factual summary of the clinical research conducted on Alopectyl (Megestrol acetate), describing the types of studies performed, the patient populations examined, and the aspects that remain uncertain.


Evidence for Severe Appetite Loss and Involuntary Weight Loss (Cachexia)

The evidence for this use is primarily derived from Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies monitored changes over defined time intervals, comparing the use of the medicine against placebo or active control treatments. Research focused on patient-reported appetite levels and objective measures of body weight change over short-term periods, observing populations with cancer-associated wasting and HIV-associated weight loss. Findings describe patterns where outcomes measured in the monitored populations differed from measurements reported in the placebo groups.


Evidence for Palliative Hormonal Treatment in Specific Cancers

Alopectyl was studied for its use as a palliative hormonal agent in specific advanced or recurrent hormone-sensitive malignancies, such as endometrial carcinoma and metastatic breast carcinoma. The research utilized older Phase II Clinical Trials and RCTs monitoring oncological endpoints like Tumor Response Rate and Overall Survival metrics. Research describes that for certain patient subgroups, data show patterns related to measurable tumor responses. However, studies exploring the use of varying doses did not consistently report superior patterns compared to lower doses regarding tumor response or survival endpoints.


Research Limitations and Uncertainty

Most available evidence for appetite and weight change comes from studies where follow-up durations were limited, typically spanning only a few months. Long-term effects are not fully established regarding the continuity of any observed symptomatic changes. Research has also explored special populations, including older adults and pediatric oncology patients, but the data for certain groups remain insufficient, and certainty remains low for making broad statements. Findings were mixed regarding Quality of Life metrics, and certainty remains low regarding whether the observed weight changes represent an improvement in muscle mass. Comparative evidence is limited against certain newer therapeutic approaches. These research limitations show that the evidence contributes to the broader evidence landscape but research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Alopectyl (FAQ)


Q: How long does it usually take before a person might notice effects from Alopectyl?

A: Regulatory documents state that for its intended uses, continuous administration for at least two months is generally considered an adequate period for a healthcare provider to determine the intended effect. While clinical literature suggests the onset of action for appetite and weight change may take a few weeks, the full period is needed for a proper evaluation.


Q: What happens if a person stops using Alopectyl suddenly?

A: If the medicine is stopped abruptly after chronic use, clinical cases of adrenal insufficiency have been observed. This condition may lead to adrenal suppression, which is a serious risk that may require monitoring and supportive treatment upon withdrawal. Information regarding the discontinuation of this product should be discussed with a healthcare provider.


Q: Do official sources discuss the possibility of sexual side effects with Alopectyl?

A: Yes, official product information lists adverse reactions that affect sexual function. These include impotence (erectile dysfunction) in men. For women, side effects such as breakthrough bleeding, changes in menstrual flow, and hot flashes have been reported.


Q: Is Alopectyl compatible with hair treatments like coloring or perming?

A: Alopectyl (Megestrol acetate) is an oral medication taken as a tablet or liquid suspension, not a topical product applied to the scalp or hair. The official product information does not include data on the compatibility of this oral medication with hair treatments.


Q: Do I need to keep using Alopectyl indefinitely to maintain its effects?

A: The official duration of treatment is determined on an individual basis based on the continued need for the medicine's palliative effect. Regulatory documents do not define a maximum duration of therapy, but treatment often continues as long as the beneficial effect is maintained or until discontinuation is medically necessary.


Q: Does Alopectyl interact with common vitamins or dietary supplements?

A: While regulatory drug interaction studies focus on certain prescription medications like HIV antivirals and blood thinners, common vitamins and supplements are not specifically listed as formal interactions. Regulatory sources generally recommend patients discuss all supplements and non-prescription products they are taking with a healthcare professional.


Q: Are there any common food or drink interactions with Alopectyl besides alcohol?

A: The official administration instructions for the concentrated liquid suspension state that it can be taken without regard to meals. No specific non-alcoholic foods or drinks are formally listed as known interactions that would alter the drug's effect, though its absorption may be affected by certain intestinal factors.


Q: Is Alopectyl a first-line treatment for its main indications?

A: Official information describes Alopectyl's use as a palliative treatment for advanced cancers and for anorexia/cachexia in certain patient populations. It is often used after underlying causes of weight loss have been addressed or in the context of advanced disease, and it is typically not described as a primary curative agent.


Q: What should be done if a dose of Alopectyl is missed?

A: Regulatory patient information describes that a missed dose may be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped entirely. Official guidance cautions against taking a double dose to compensate for the missed amount.


Q: Can Alopectyl cause unwanted hair growth on the body?

A: The official adverse reaction lists include alopecia (hair loss), but they do not list hirsutism (unwanted or excessive hair growth) as a common or serious reported side effect of Alopectyl (Megestrol acetate).


Q: What is the typical risk of an allergic reaction to Alopectyl?

A: A known allergy or hypersensitivity to megestrol acetate or any component in the formulation is an absolute contraindication, meaning the drug must not be used by those with this history. Regulatory documents define the seriousness of this risk but do not quantify the general likelihood of a person developing a new allergic reaction.


Q: Why is consistency of use mentioned as being important for Alopectyl?

A: Consistency is important because the medicine is generally taken regularly to achieve the most benefit. Clinical pharmacology information indicates that with repeated, consistent dosing, the drug's levels in the body are expected to increase daily, reaching stable, predictable levels after a few days.


Q: What are the specific recommendations for Alopectyl use in elderly patients?

A: Official guidelines recommend that dose selection for older adults should be cautious, typically starting at the lower end of the official dosing range. This approach accounts for the greater likelihood of reduced organ function with age, and close monitoring of parameters such as renal function may be required.


Q: Does using more Alopectyl than recommended increase the risk of side effects?

A: Official patient counseling states that increasing the dose beyond what is recommended will not speed up the improvement of the condition. Instead, it will increase the risk of experiencing side effects. Overdose symptoms may include specific issues like listlessness and shortness of breath.

How should Alopectyl be stored and disposed of?

How to Store and Dispose of Alopectyl? (Minoxidil Topical Solution)

Official regulatory guidelines require Alopectyl to be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), though a range of 15 C to 30 C may also be stated. The container must be kept tightly closed and stored upright.

Storage Constraints:

Because the solution is officially classified as a flammable liquid, it must be stored away from excessive heat, open flames, and lit cigarettes. Handling instructions warn against breathing vapors and mandate washing hands after use.

Disposal Requirements:

To prevent accidental exposure, this product must be kept out of the reach of children. The container and any unused medicine must be disposed of according to local and national regulations for hazardous or flammable waste at an appropriate treatment and disposal facility.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alopectyl found in:

A-Z Index: